Use and abuse of dissociative and psychedelic drugs in adolescence
M.l. Shawn Bates, Keith A Trujillo
Pharmacology, Biochemistry, and Behavior January 27, 2021 DOI: 10.1016/j.pbb.2021.173129 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Population | Adolescent humans and preclinical animal models |
| Topics | Addiction MDMA Psilocybin |
| Keywords | Hallucinogen Substance abuse Clinical psychology Developmental psychology Drugs of abuse |
| Citations | 57 |
| Key findings | Very little is known about the effects of dissociatives, classic psychedelics, and MDMA in adolescents, though emerging evidence suggests the balance of reinforcing and aversive effects may differ between adolescents and adults, with implications for drug use and addiction. |
Abstract
Adolescence is a period of profound developmental changes, which run the gamut from behavioral and neural to physiological and hormonal. It is also a time at which there is an increased propensity to engage in risk-taking and impulsive behaviors like drug use. This review examines the human and preclinical literature on adolescent drug use and its consequences, with a focus on dissociatives (PCP, ketamine, DXM), classic psychedelics (LSD, psilocybin), and MDMA. It is the case for all the substances reviewed here that very little is known about their effects in adolescent populations. An emerging aspect of the literature is that dissociatives and MDMA produce mixed reinforcing and aversive effects and that the balance between reinforcement and aversion may differ between adolescents and adults, with consequences for drug use and addiction. However, many studies have failed to directly compare adults and adolescents, which precludes definitive conclusions about these consequences. Other important areas that are largely unexplored are sex differences during adolescence and the long-term consequences of adolescent use of these substances. We provide suggestions for future work to address the gaps we identified in the literature. Given the widespread use of these drugs among adolescent users, and the potential for therapeutic use, this work will be crucial to understanding abuse potential and consequences of use in this developmental stage.
In the evidence
This study is part of the evidence base for a synthesis in the library. Here is how each one recorded it.
-
Notes that little is known about MDMA effects in adolescents and that MDMA produces mixed reinforcing and aversive effects whose balance may differ between adolescents and adults.
Synthesized
Comparable studies
Other narrative reviews on MDMA for addiction, most cited first.
Citations in the library
Cited by 38
- Ethical and Practical Considerations for the Use of Psychedelics in Psychiatry Psychiatric Services March 29, 2023
- Exploring protective associations between the use of classic psychedelics and cocaine use disorder: a population-based survey study Scientific Reports February 16, 2022
- Set and setting predict psychopathology, wellbeing and meaningfulness of psychedelic experiences: a correlational study. Expert Review of Clinical Pharmacology 2024
- Potential Therapeutic Effects of Psilocybin: A Systematic Review. Cureus October 1, 2022
- Acid liberalism: Silicon Valley's enlightened technocrats, and the legalization of psychedelics. International Journal of Drug Policy December 1, 2022
and 33 more in the library
Cites 118
- Subanesthetic Effects of the Noncompetitive NMDA Antagonist, Ketamine, in Humans Archives of General Psychiatry March 1, 1994
- Recent advances in the phencyclidine model of schizophrenia American Journal of Psychiatry October 1, 1991
- Mechanisms of Ketamine Action as an Antidepressant Molecular Psychiatry March 13, 2018
- Study of a New Schizophrenomimetic Drug—Sernyl Archives of Neurology And Psychiatry March 1, 1959
- NMDA Antagonist Neurotoxicity: Mechanism and Prevention Science December 6, 1991
and 113 more in the library